The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis
Authors
Keywords
Multiple Sclerosis, Experimental Autoimmune Encephalomyelitis, Progressive Multifocal Leukoencephalopathy, Natalizumab, Fingolimod
Journal
CNS DRUGS
Volume 30, Issue 2, Pages 135-147
Publisher
Springer Nature
Online
2015-12-29
DOI
10.1007/s40263-015-0297-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis
- (2015) Nicola De Stefano et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Switching from natalizumab to fingolimod
- (2015) Ludwig Kappos et al. NEUROLOGY
- Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis
- (2015) E.-W. Radue et al. NEUROLOGY
- Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial
- (2015) L. Kappos et al. NEUROLOGY
- Tissue Distribution Dynamics of Human NK Cells Inferred from Peripheral Blood Depletion Kinetics after Sphingosine-1-Phosphate Receptor Blockade
- (2015) M. Mehling et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?
- (2015) Simona F. Spampinato et al. PLoS One
- Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid β-induced memory impairment
- (2014) Kazuya Fukumoto et al. BEHAVIOURAL BRAIN RESEARCH
- The sphingosine 1-phosphate receptor agonist FTY720 is neuroprotective after cuprizone-induced CNS demyelination
- (2014) A Slowik et al. BRITISH JOURNAL OF PHARMACOLOGY
- Clinical Relevance of Brain Volume Measures in Multiple Sclerosis
- (2014) Nicola De Stefano et al. CNS DRUGS
- Systemic distribution, subcellular localization and differential expression of sphingosine-1-phosphate receptors in benign and malignant human tissues
- (2014) Chunyi Wang et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- Mechanisms of white matter damage in multiple sclerosis
- (2014) Hans Lassmann GLIA
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis
- (2014) Frederik Barkhof et al. Multiple Sclerosis Journal
- Fingolimod after natalizumab and the risk of short-term relapse
- (2014) V. G. Jokubaitis et al. NEUROLOGY
- Investigation of immune and CNS-mediated effects of fingolimod in the focal delayed-type hypersensitivity multiple sclerosis model
- (2014) Daniel C. Anthony et al. NEUROPHARMACOLOGY
- Fingolimod Attenuates Splenocyte-Induced Demyelination in Cerebellar Slice Cultures
- (2014) Adam J. Pritchard et al. PLoS One
- Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study
- (2014) Nele Claes et al. PLoS One
- Switching From Natalizumab to Fingolimod in Multiple Sclerosis
- (2014) Mikael Cohen et al. JAMA Neurology
- Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings
- (2014) Ludwig Kappos et al. Multiple Sclerosis and Related Disorders
- Insufficient OPC migration into demyelinated lesions is a cause of poor remyelination in MS and mouse models
- (2013) Amanda Boyd et al. ACTA NEUROPATHOLOGICA
- Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis
- (2013) Maria Pia Sormani et al. ANNALS OF NEUROLOGY
- The astrocyte in multiple sclerosis revisited
- (2013) Celia F. Brosnan et al. GLIA
- Fingolimod phosphate promotes the neuroprotective effects of microglia
- (2013) Hiromi Noda et al. JOURNAL OF NEUROIMMUNOLOGY
- Dual effects of daily FTY720 on human astrocytes in vitro: relevance for neuroinflammation
- (2013) Celina Wu et al. Journal of Neuroinflammation
- Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy
- (2013) Aran Groves et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Origins and significance of astrogliosis in the multiple sclerosis model, MOG peptide EAE
- (2013) Monica Moreno et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy
- (2013) G Francis et al. Multiple Sclerosis Journal
- Microglia: Multiple roles in surveillance, circuit shaping, and response to injury
- (2013) E. E. Benarroch NEUROLOGY
- Immunohistochemical detection of sphingosine-1-phosphate receptor 1 and 5 in human multiple sclerosis lesions
- (2013) Corinne Brana et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- Fingolimod Phosphate Attenuates Oligomeric Amyloid β–Induced Neurotoxicity via Increased Brain-Derived Neurotrophic Factor Expression in Neurons
- (2013) Yukiko Doi et al. PLoS One
- FTY720 Treatment in the Convalescence Period Improves Functional Recovery and Reduces Reactive Astrogliosis in Photothrombotic Stroke
- (2013) Robert Brunkhorst et al. PLoS One
- The Role of Natural Killer Cells in Multiple Sclerosis and Their Therapeutic Implications
- (2013) Coralie Chanvillard et al. Frontiers in Immunology
- Fingolimod attenuates ceramide-induced blood–brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes
- (2012) Ruben van Doorn et al. ACTA NEUROPATHOLOGICA
- Sphingosine-1-Phosphate and Lymphocyte Egress from Lymphoid Organs
- (2012) Jason G. Cyster et al. Annual Review of Immunology
- Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple Sclerosis
- (2012) Ernst-Wilhelm Radue ARCHIVES OF NEUROLOGY
- Anti-CD20 Therapy Reduces Microglial Activation and Lesion Volume in Focal Models of Pattern I and Pattern II Multiple Sclerosis (P02.085)
- (2012) D. Leppert et al. NEUROLOGY
- Remyelination Therapy for Multiple Sclerosis
- (2012) Michael B. Keough et al. Neurotherapeutics
- Fingolimod protects cultured cortical neurons against excitotoxic death
- (2012) Luisa Di Menna et al. PHARMACOLOGICAL RESEARCH
- Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome
- (2012) R. Deogracias et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis
- (2011) R. A. Linker et al. BRAIN
- Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis
- (2011) S Rossi et al. BRITISH JOURNAL OF PHARMACOLOGY
- BZM055, an Iodinated Radiotracer Candidate for PET and SPECT Imaging of Myelin and FTY720 Brain Distribution
- (2011) Emmanuelle Briard et al. ChemMedChem
- Clinical Pharmacokinetics of Fingolimod
- (2011) Olivier J. David et al. CLINICAL PHARMACOKINETICS
- Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model
- (2011) Hye Jung Kim et al. FASEB JOURNAL
- S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures
- (2011) Graham K. Sheridan et al. GLIA
- Reduction of the Peripheral Blood CD56bright NK Lymphocyte Subset in FTY720-Treated Multiple Sclerosis Patients
- (2011) T. A. Johnson et al. JOURNAL OF IMMUNOLOGY
- Fingolimod modulates microglial activation to augment markers of remyelination
- (2011) Samuel J Jackson et al. Journal of Neuroinflammation
- Remyelination Is Altered by Bone Morphogenic Protein Signaling in Demyelinated Lesions
- (2011) J. K. Sabo et al. JOURNAL OF NEUROSCIENCE
- Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo
- (2011) Yinghui Hu et al. MOLECULAR AND CELLULAR NEUROSCIENCE
- Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS
- (2011) M. C. Kowarik et al. NEUROLOGY
- Physiology of Microglia
- (2011) Helmut Kettenmann et al. PHYSIOLOGICAL REVIEWS
- Fingolimod (FTY720) Enhances Remyelination Following Demyelination of Organotypic Cerebellar Slices
- (2010) Veronique E. Miron et al. AMERICAN JOURNAL OF PATHOLOGY
- Distinct Properties of Circulating CD8+ T Cells in FTY720-Treated Patients With Multiple Sclerosis
- (2010) Trina A. Johnson et al. ARCHIVES OF NEUROLOGY
- Cells of the oligodendroglial lineage, myelination, and remyelination
- (2010) Veronique E. Miron et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
- (2010) Jerold Chun et al. CLINICAL NEUROPHARMACOLOGY
- Astrocyte-Restricted Ablation of Interleukin-17-Induced Act1-Mediated Signaling Ameliorates Autoimmune Encephalomyelitis
- (2010) Zizhen Kang et al. IMMUNITY
- Differential responses of human microglia and blood-derived myeloid cells to FTY720
- (2010) Bryce A. Durafourt et al. JOURNAL OF NEUROIMMUNOLOGY
- Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
- (2010) Volker Brinkmann et al. NATURE REVIEWS DRUG DISCOVERY
- Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
- (2010) N. De Stefano et al. NEUROLOGY
- Sphingolipids in Multiple Sclerosis
- (2010) Arundhati Jana et al. NEUROMOLECULAR MEDICINE
- Intrathecal increase of sphingosine 1-phosphate at early stage multiple sclerosis
- (2010) Alina Kułakowska et al. NEUROSCIENCE LETTERS
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation
- (2010) J. W. Choi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The cuprizone animal model: new insights into an old story
- (2009) Markus Kipp et al. ACTA NEUROPATHOLOGICA
- The relation between inflammation and neurodegeneration in multiple sclerosis brains
- (2009) Josa M. Frischer et al. BRAIN
- FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system
- (2009) Volker Brinkmann BRITISH JOURNAL OF PHARMACOLOGY
- Proof of concept studies for tissue-protective agents in multiple sclerosis
- (2009) LR Mehta et al. Multiple Sclerosis Journal
- Cyclical and Dose-Dependent Responses of Adult Human Mature Oligodendrocytes to Fingolimod
- (2008) Veronique E. Miron et al. AMERICAN JOURNAL OF PATHOLOGY
- FTY720 Rescue Therapy in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis: Expression of Central Nervous System Genes and Reversal of Blood-Brain-Barrier Damage
- (2008) Carolyn A. Foster et al. BRAIN PATHOLOGY
- Astrocytes in multiple sclerosis: A product of their environment
- (2008) A. Nair et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- 17β-estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice
- (2008) Peter Acs et al. GLIA
- Multiple sclerosis
- (2008) Alastair Compston et al. LANCET
- FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis
- (2008) M. Mehling et al. NEUROLOGY
- FTY720 modulates human oligodendrocyte progenitor process extension and survival
- (2007) Veronique E. Miron et al. ANNALS OF NEUROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started